Palatin reported promising results in trial for ulcerative colitis treatment
Source: SeekingAlpha
2025-03-28 09:19:02 ET
More on Palatin Technologies
- Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript
- Palatin's gets Orphan Drug status for its treatment for obesity from genetic disorder
- Palatin Technologies prices 4.69M shares in direct offering
- Seeking Alpha’s Quant Rating on Palatin Technologies
- Historical earnings data for Palatin Technologies
Read the full article on Seeking Alpha
For further details see:
Palatin reported promising results in trial for ulcerative colitis treatment
Palatin Technologies Inc.
NASDAQ: PTN
PTN Trading
1.6% G/L:
$21.90 Last:
5,336 Volume:
$22 Open:
PTN Latest News
February 17, 2026 07:30:00 am
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
November 13, 2025 07:30:00 am
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
PTN Stock Data
$28,009,174
1,546,029
10.97%
7
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
